An online tool combining results of common medical tests can accurately estimate the risk of whether someone with chronic kidney disease will develop kidney failure in the next two to five years, an international team of researchers led by the Johns Hopkins Bloomberg School of Public Health has found.
Reporting in the Jan. 12, 2016 Journal of the American Medical Association (JAMA), the researchers say the new calculator will not only help patients at high risk for kidney failure prepare for dialysis or transplant, but could provide peace of mind to millions more who have chronic kidney disease but are not at serious risk of kidney failure.
Researchers estimate that 10 percent of the U.S. population -- more than 20 million people -- has kidney disease and more than 660,000 people have kidney failure requiring either dialysis to mechanically clean the blood or a kidney transplant. In 2013, 117,000 patients developed kidney failure, meaning that approximately one percent of those with chronic kidney disease develop kidney failure every two years.
"This tool allows doctors to sit down with their patients and explain how likely it is that their kidneys will fail in the near future," says Josef Coresh, MD, PhD, the George W. Comstock Professor of Epidemiology at the Bloomberg School, and head of the Chronic Kidney Disease Prognosis Consortium, which conducted the study. "While the tool can aid in management of a patient's disease and prepare them for the worst, many more patients will find the results reassuring. You can reassure a lot of worried people with the fact that their risk is actually very low. The vast majority of patients will not need dialysis."
Building on a tool created by Canadian researchers studying Canadian patients, the Consortium validated the tool using data from more than 721,000 people in 30 countries. They found that a four-variable risk calculator accurately predicted the risk of kidney failure in two or five years, and an eight-variable calculator did moderately better. The four-variable risk calculator uses age, sex, an estimate of kidney function based on a blood test and the amount of protein in the urine, while the eight-variable risk calculator adds blood calcium, phosphate, bicarbonate and albumin levels. The second set of laboratory tests isn't as widely done in clinical practice as the first.
The researchers found that the results in the United States were similar to those in the original Canadian study. They also found that, in countries outside North America, the risk tool needed slight adjustment to account for the lower kidney failure risk in these countries. The researchers hypothesize that the lower risk in countries outside North America could be because physicians in some countries may be less likely to refer patients for life-extending dialysis or because they may be better at treating kidney disease.
The Canadian tool had been criticized because the model included little data from African-Americans with kidney disease. African-Americans have the highest rates of kidney disease in the U.S. Including this population did not change the validity of the tool since it included variables that capture the excess risk, the researchers found.
"We've known which were the important tests to consider in determining the risk of kidney failure, but we didn't know exactly how to put them together and we didn't have a high level of confidence that this tool could be used widely," Coresh says. "Now we do."
The tool, which will be live http://www.
"Dialysis and transplantation are expensive and complicated and take planning," says study co-author Morgan E. Grams, MD, PhD, a nephrologist and assistant professor of epidemiology at the Bloomberg School. "Knowing ahead of time allows people to consider their options."
"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis" was written by Navdeep Tangri, MD, PhD; Morgan E. Grams, MD, PhD; Andrew S. Levey, MD; Josef Coresh, MD, PhD; Lawrence Appel, MD; Brad C. Astor, PhD, MPH; Gabriel Chodick, PhD; Allan J. Collins, MD; Ognjenka Djurdjev, MSc; C. Raina Elley, MBCHB, PhD; Marie Evans, MD, PhD; Amit X. Garg, MD, PhD; Stein I. Hallan, MD, PhD; Lesley Inker, MD, MS; Sadayoshi Ito, MD, PhD; Sun Ha Jee, PhD; Csaba P. Kovesdy, MD; Florian Kronenberg, MD; Hiddo J. Lambers Heerspink, PharmD, PhD; Angharad Marks, MBBCh, MRCP, MSc, PhD; Girish N. Nadkarni, MD, MPH; Sankar D. Navaneethan, MD, MPH; Robert G. Nelson, MD, PhD; Stephanie Titze, MD, MSc; Mark J. Sarnak, MD, MS; Benedicte Stengel, MD, PhD; Mark Woodward, PhD and Kunitoshi Iseki, MD, PhD for the Chronic Kidney Disease Prognosis Consortium (CKD-PC).
The CKD-PC Data Coordinating Center is funded in part by a program grant from the U.S. National Kidney Foundation (NKF funding sources include AbbVie, Amgen, and Merck) and the National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100446-01). A variety of sources have supported enrollment and data collection including laboratory measurements, and follow-up in the collaborating cohorts of the CKD-PC. These funding sources include government agencies such as national institutes of health and medical research councils as well as foundations and industry sponsors.